- Docket No.
- 3:23-cv-00058
- District Court
- West Virginia
Goal
- Enjoin state from enforcing state law
- Invalidate part of a state statute
Issues
Case History
Litigation Content
Why this Matters:
The Plaintiff alleges that West Virginia’s abortion ban, which effectively bans the sale of mifepristone in the state, conflicts with the Food and Drug Administration’s (FDA’s) federal approval of the drug. Ensuring that individuals have access to FDA-approved medication abortions enables patients to receive necessary reproductive health care.
Potential Impact:
Overriding the FDA’s expertise and preventing individuals from accessing effective medication for abortion services will jeopardize their health and safety.
25 Major Filings
- Memorandum in Support of Motion to Dismiss by Mark A. Sorsaia (Feb 16, 2024)
- Notice of Appeal (Nov 9, 2023)
- Order Dismissing First Amended Complaint (Nov 6, 2023)
- Motion for Final Judgement on First Amended Complaint (Nov 3, 2023)
- First Amended Complaint (Oct 19, 2023)
- Memorandum and Order Granting in Part Motions to Dismiss (Aug 24, 2023)
- NOTICE of Supplemental Authority by GenBioPro, Inc. (Aug 18, 2023)
- Hearing Transcript (May 30, 2023)
- SUPPLEMENTAL BRIEFING by GenBioPro, Inc. (May 19, 2023)
- SUPPLEMENTAL BRIEFING by Patrick Morrisey (May 19, 2023)
- Order for Supplemental Briefing (May 11, 2023)
- Memorandum and Order Denying in Part Motions to Dismiss (May 2, 2023)
- Order Denying Motion to Stay (Apr 21, 2023)
- Reply to Opposition to Motion to Stay (Apr 21, 2023)
- Opposition to Motion to Stay (Apr 20, 2023)
- Memorandum in Support of Motion to Stay (Apr 18, 2023)
- Motion to Stay (Apr 18, 2023)
- Reply to Response to Motion to Dismiss (Mar 31, 2023)
- Amicus Brief by Health Law Scholars (Mar 27, 2023)
- Opposition to Motion to Dismiss (Mar 17, 2023)
- Amicus Brief by Florida et al (Mar 6, 2023)
- Memorandum in Support of Motion to Dismiss by Patrick Morrisey (Feb 21, 2023)
- Motion to Dismiss by Patrick Morrisey (Feb 21, 2023)
- Motion to Dismiss by Mark A. Sorsaia (Feb 16, 2023)
- Complaint (Jan 25, 2023)